Vasacad-S (Sacubritil + Valsartan)

Sacubitril + Valsartan is a combination therapy classified as an angiotensin receptor–neprilysin inhibitor (ARNI), designed for the treatment of chronic heart failure in adults and children aged 1 year and older. This dual‑action medication combines:

• Sacubitril, a neprilysin inhibitor that increases beneficial natriuretic peptides, promoting blood vessel relaxation and reduced fluid retention.
• Valsartan, an angiotensin II receptor blocker (ARB) that reduces vascular tightening and lowers blood pressure.

Together, they work synergistically to improve heart function, lower hospitalization risk, and reduce cardiovascular death in heart‑failure patients with reduced ejection fraction. Clinical trials and real‑world studies consistently show improved outcomes compared to conventional ACE‑inhibitor therapy. This category includes tablets and sprinkle capsules/pellets suitable for adults, adolescents, and pediatric patients. Dosage strengths vary to support initiation, titration, and long‑term maintenance. All formulations in this category are sourced from trusted pharmaceutical manufacturers, ensuring reliable potency, consistent release performance, and strict quality standards.